Rabisin, a veterinary immunological agent, may be part of symptomatic management used for active immunization to help manage the risk of the life-threatening viral disease caused by the rabies virus (a Lyssavirus). This vaccine is commonly used to help manage the risk associated with conditions presenting with systemic or localized discomfort related to potential exposure.

The primary use is considered relevant for managing the risk of infection in susceptible domestic animals, particularly dogs and cats. Vaccination as a preventative measure helps with reducing exposures. The benefit to the animal is the management of risk associated with the fatal neurological progression and the devastating acute neurological and behavioral manifestations that characterize the disease. It is considered relevant for managing the risk of terminal neurological progression and is applied in addressing the associated severe symptomatic outcomes.

It is applied in clinical settings that involve acute or unstable symptom patterns related to potential exposure, such as routine periodic immunization schedules and risk mitigation in high-exposure scenarios. The vaccine’s widespread use provides support for pet health and contributes to public health objectives by reducing the zoonotic risk.

Quick Fact: Prophylaxis for Fatal Disease Rabisin is commonly used to help with preventing the disease state entirely, which provides support that helps ease the overall risk associated with an almost universally fatal condition.

Official Population Eligibility for Rabisin

Regulatory agencies define the eligibility for the veterinary immunological agent Rabisin based on the animal's species, age, and general health status. This information is derived exclusively from the official product labeling, such as the Summary of Product Characteristics (SPC).

Eligibility scope	Official Regulatory Statement
Target Species (Allowed)	Primarily dogs and cats for active immunization. Some regional licenses extend to other species, including horses, cattle, sheep, and ferrets.
Contraindications	None. The official label specifies no absolute contraindications (prohibitions) for this vaccine.
Condition-Specific Exclusion	A formal restriction states that the vaccine must not be administered to unhealthy animals; only healthy animals are eligible for vaccination.
Pregnancy Eligibility	Use of the vaccine can be used during pregnancy is explicitly permitted in the official documentation.

Age-Related Eligibility Rules

For dogs and cats, the primary vaccination course begins from 12 weeks of age. However, a specific conditional rule applies: if a dog or cat is vaccinated before this 12-week threshold, the official scheme must be completed by an additional injection administered at 12 weeks of age or older. This ensures the animal meets the full regulatory standard for immunization.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Rabisin, an inactivated rabies vaccine, primarily around physical compatibility and specific co-administration rules. As an immunological agent, the product lacks documented information regarding metabolic or transporter-mediated pharmacokinetic interactions, such as those involving Cytochrome P450 enzymes.

---

Interaction Constraints and Restrictions

Category	Officially Documented Restriction
Physical Incompatibility	The product must not be physically mixed with any other veterinary medicinal product in the same syringe or vial.
Pharmacodynamic Interactions	No safety or efficacy information is available for co-administration with most other veterinary medicinal products.

---

Specific Co-administration Protocol

Rabisin can be administered on the same day as Boehringer Ingelheim’s PUREVAX non-adjuvanted vaccines for cats. However, to adhere to the officially documented protocol, the two products must be given at different injection sites to maintain their individual integrity and intended effect. For all other combinations, the regulatory documentation states that a decision to co-administer must be made on a case-by-case basis due to the absence of specific interaction data. There are no documented interactions with food, alcohol, herbal products, or supplements.

Rabisin introduces inactivated viral antigens derived from the rabies virus, serving as the biological target for antigen-presenting cells ( APCs). These APCs internalize the antigens and present them to T-helper cells ( CD4+ T cells), thereby initiating the cell-mediated immune cascade.

The activated T-helper cells subsequently provide the necessary signal to B-lymphocytes, driving them to undergo clonal expansion and differentiate into plasma cells. This downstream cascade results in the secretion of high titers of specific neutralizing antibodies ( Immunoglobulin G) ( IgG). These IgG molecules exhibit specific affinity for the rabies virus glycoprotein, binding to and physically neutralizing the circulating virus. This process establishes the system-level physiological consequence of immunological memory, characterized by the persistence and rapid mobilization of memory B and T cells upon subsequent encounter with the virus.

Rabisin is an inactivated vaccine intended for use in animals, primarily dogs and cats, following a standardized administration protocol. The product is administered as a 1 mL suspension for injection using a parenteral route, typically via subcutaneous (SC) injection, though the intramuscular route is also utilized. This volume is uniform and does not require adjustment based on the animal's size or weight.

The usage is structured around a precise timing pattern. The primary vaccination involves a single injection given only once the animal is 12 weeks of age or older. For those animals vaccinated before this age, a follow-up injection is administered at 12 weeks of age or later to complete the initial protective course. This specific timing establishes the foundation for subsequent use.

The regimen transitions to a booster cycle designed to maintain long-term protection. The first re-vaccination dose is required one year after the primary course is completed. Subsequent administration is then performed at intervals of up to three years, establishing the re-vaccination cycle. Procedural requirements state that the suspension should be used immediately after opening the vial and must not be mixed with any other veterinary medicinal product prior to injection, a constraint that defines proper handling during the administration process.

Research Evidence / Overview of Studies for Rabisin

This overview summarizes the formal research available regarding the veterinary vaccine Rabisin, focusing on the types of studies conducted, the outcomes research examined, and what areas remain uncertain, according to regulatory and peer-reviewed scientific sources.

---

Evidence for Achieving Initial Protection (Primary Vaccination)

Research has primarily been conducted using controlled immunogenicity studies and experimental challenge studies to explore the initial immune response patterns to the vaccine. These studies were applied in research contexts involving healthy domestic animals, specifically dogs and cats, to explore the initial immune response patterns.

Studies monitored outcomes related to the production of Viral Neutralizing Antibodies (VNA), which are used as a primary outcome measure for evidence of potential protection. Researchers examined the proportion of vaccinated animals that reached a specific protective antibody level, often one month after the vaccination. Findings describe patterns observed in the studies where antibody levels met the international protective threshold in observed populations within that short-term period.

What remains uncertain is the reliance on VNA titer, as it is a correlate of protection (a surrogate marker), and long-term clinical challenge survival data are not fully established at the maximum authorized intervals. Furthermore, findings were mixed when comparing antibody response patterns across different products in some trials.

Evidence on Sustaining Protection (Booster Schedules and Duration)

Research examined the persistence of the immune response over time, which contributes to research exploring the persistence of the immune response over extended time intervals. This evidence was evaluated in longitudinal studies that monitored antibody production over extended periods in previously vaccinated adult dogs and cats. These studies explored the duration of immunity (DOI) for protocols relevant in research exploring persistence patterns across one-year and multi-year intervals.

Studies monitored patterns where antibody levels remained above the protective threshold in observed cohorts for specific time periods. Research described patterns related to the antibody levels measured following the administration of a booster dose. Evidence also contributes to the broader evidence landscape by providing insight into short-term changes in immunity across defined time intervals.

However, long-term effects are not fully established based on direct clinical challenge studies at the three-year mark; the data for this extended period are mainly derived from long-term serology measurements (antibody titers). Data for certain groups, such as very old animals or those with other health conditions, remain insufficient to draw broad conclusions about the consistency of long-term immune maintenance across all populations.

Evidence in Specific Animal Populations and Field Use

Research has examined the vaccine response across different groups. Studies explored how the immune response was measured in young animals, such as puppies, where potential interference from the mother's antibodies can occur. These findings contribute to understanding the antibody response patterns in this population. Comparative evidence from large-scale retrospective analyses has also monitored antibody levels in dogs versus cats, with studies describing different antibody response patterns observed in cats compared to those observed in dogs.

Additionally, field studies explored the vaccine's application in research contexts involving large-scale mass vaccination programs, particularly those focused on controlling the disease in high-risk areas. Research describes how these studies monitored the overall antibody response within large groups of free-roaming dogs, with findings helping contextualize how factors like animal health and compliance were associated with observed antibody levels in these field settings.

What Remains Unclear or Under-Studied

While the research provides context for understanding symptom patterns related to initial and long-term protection, several areas of uncertainty remain. Evidence quality varies across studies, and comparative evidence detailing direct, long-term efficacy across all commercially available vaccines is not fully established.

As noted, the primary outcome measure used in research for long-term assessment is the measurement of antibody titer, and research is ongoing to fully characterize the relationship between these antibody levels and guaranteed clinical protection over extended periods (e.g., three years) in every individual animal. Furthermore, research provides insight into short-term changes, but there is limited information for long-term outcomes in specific subgroups, such as older or immunocompromised animals. Findings describe group patterns; research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Analysis of Rabies Vaccine Antibody Titres in Dogs and Cats for Travel Schemes (Simulated Large Observational Study)

Common questions about Rabisin (FAQ)

---

Q: How does the aluminum hydroxide in Rabisin help the vaccine work?

Rabisin contains Aluminum (as hydroxide), which is listed in the official product information as an adjuvant. Adjuvants are components added to a vaccine formulation to support and stimulate the animal's immune response against the rabies virus.

---

Q: What happens if I accidentally freeze the Rabisin vial?

Regulatory storage guidelines state that Rabisin must be kept refrigerated, specifically between +2 C and +8 C, and should not be frozen. If the vaccine is exposed to freezing temperatures, it is considered compromised according to regulatory guidelines.

---

Q: Does Rabisin have any known food or drug interactions?

Official information indicates the product lacks documented information regarding metabolic or transporter-mediated pharmacokinetic interactions, such as those involving Cytochrome P450 enzymes. However, no specific safety or efficacy data are available for its use with most other veterinary medicinal products. Official product information does not list documented interactions with food, alcohol, or common supplements.

---

Q: What should I do if my pet is not a dog or cat? Can I still use Rabisin?

The official product documentation primarily names dogs and cats as the target species for Rabisin. While the vaccine may hold regional licenses for use in other species, such as ferrets, horses, cattle, or sheep, the decision to vaccinate should be made by a veterinarian based on local authorization for that specific animal type.

---

Q: Can Rabisin be administered intravenously (IV)?

The authorized and documented routes for administering Rabisin are strictly subcutaneous (SC) or intramuscular (IM) injection. Official product information does not include or authorize the use of the intravenous (IV) route for administration.

---

Q: What are the risks of vaccinating an animal that is already showing symptoms of rabies?

The vaccine is indicated for active immunisation to prevent rabies, meaning it is intended for use before exposure or symptoms occur. The regulatory text specifies that Rabisin should be administered only to healthy animals. The product information does not provide data or guidance on the risks or outcomes of administering the vaccine to an animal that is already displaying symptoms of rabies.

---

Q: How soon after the primary shot is the animal considered protected?

Research evidence in the regulatory documentation indicates that immunity is demonstrated one month after the primary vaccination course is completed. This level of protection has been shown to persist up until the time the first booster dose is required.

Storage and Disposal Requirements for Rabisin

Rabisin (Rabies virus, Inactivated) requires strict storage conditions as defined in official regulatory labeling to ensure its stability.

Official Storage Conditions

Requirement	Constraint
Storage Temperature	Must be refrigerated between +2°C and +8°C (35°F to 46°F).
Prohibited Environment	Do not freeze; freezing will compromise the vaccine.
Protection	Must be protected from light.
Child Safety	Keep out of the sight and reach of children.
Post-Opening Use	The product must be used immediately after opening the vial.

Disposal Instructions

Any unused veterinary medicinal product or waste material derived from its use must be disposed of in accordance with local requirements for pharmaceutical and medical waste.